187 related articles for article (PubMed ID: 35500459)
1. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma.
Pamporaki C; Prodanov T; Meuter L; Berends AMA; Bechmann N; Constantinescu G; Beuschlein F; Remde H; Januszewicz A; Kerstens MN; Timmers HJLM; Taïeb D; Robledo M; Lenders JWM; Pacak K; Eisenhofer G
Eur J Cancer; 2022 Jul; 169():32-41. PubMed ID: 35500459
[TBL] [Abstract][Full Text] [Related]
2. Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.
Rao D; Peitzsch M; Prejbisz A; Hanus K; Fassnacht M; Beuschlein F; Brugger C; Fliedner S; Langton K; Pamporaki C; Gudziol V; Stell A; Januszewicz A; Timmers HJLM; Lenders JWM; Eisenhofer G
Eur J Endocrinol; 2017 Aug; 177(2):103-113. PubMed ID: 28476870
[TBL] [Abstract][Full Text] [Related]
3. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
4. Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma.
Eisenhofer G; Deutschbein T; Constantinescu G; Langton K; Pamporaki C; Calsina B; Monteagudo M; Peitzsch M; Fliedner S; Timmers HJLM; Bechmann N; Fankhauser M; Nölting S; Beuschlein F; Stell A; Fassnacht M; Prejbisz A; Lenders JWM; Robledo M
Clin Chem Lab Med; 2020 Oct; 59(2):353-363. PubMed ID: 33001846
[TBL] [Abstract][Full Text] [Related]
5. Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort.
Pamporaki C; Berends AMA; Filippatos A; Prodanov T; Meuter L; Prejbisz A; Beuschlein F; Fassnacht M; Timmers HJLM; Nölting S; Abhyankar K; Constantinescu G; Kunath C; de Haas RJ; Wang K; Remde H; Bornstein SR; Januszewicz A; Robledo M; Lenders JWM; Kerstens MN; Pacak K; Eisenhofer G
Lancet Digit Health; 2023 Sep; 5(9):e551-e559. PubMed ID: 37474439
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas.
Pamporaki C; Hamplova B; Peitzsch M; Prejbisz A; Beuschlein F; Timmers HJLM; Fassnacht M; Klink B; Lodish M; Stratakis CA; Huebner A; Fliedner S; Robledo M; Sinnott RO; Januszewicz A; Pacak K; Eisenhofer G
J Clin Endocrinol Metab; 2017 Apr; 102(4):1122-1132. PubMed ID: 28324046
[TBL] [Abstract][Full Text] [Related]
7. Laboratory evaluation of pheochromocytoma and paraganglioma.
Eisenhofer G; Peitzsch M
Clin Chem; 2014 Dec; 60(12):1486-99. PubMed ID: 25332315
[TBL] [Abstract][Full Text] [Related]
8. Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas.
Araujo-Castro M; García Sanz I; Mínguez Ojeda C; Hanzu F; Mora M; Vicente A; Blanco Carrera C; de Miguel Novoa P; López García MDC; Lamas C; Manjón-Miguélez L; Del Castillo Tous M; Rodríguez de Vera P; Barahona San Millán R; Recasens M; Tomé Fernández-Ladreda M; Valdés N; Gracia Gimeno P; Robles Lazaro C; Michalopoulou T; Álvarez Escolá C; García Centeno R; Barca-Tierno V; Herrera-Martínez AD; Calatayud M
Front Endocrinol (Lausanne); 2023; 14():1279828. PubMed ID: 38155946
[TBL] [Abstract][Full Text] [Related]
9. Analysis of plasma 3-methoxytyramine, normetanephrine and metanephrine by ultraperformance liquid chromatography-tandem mass spectrometry: utility for diagnosis of dopamine-producing metastatic phaeochromocytoma.
Peitzsch M; Prejbisz A; Kroiß M; Beuschlein F; Arlt W; Januszewicz A; Siegert G; Eisenhofer G
Ann Clin Biochem; 2013 Mar; 50(Pt 2):147-55. PubMed ID: 23512172
[TBL] [Abstract][Full Text] [Related]
10. Detection of spot urinary free metanephrines and 3-methoxytyramine with internal reference correction for the diagnosis of pheochromocytomas and paragangliomas.
Wang H; Zhang X; Zhen Q; Zou W; Chen H; Luo C; Ding M
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Nov; 1156():122306. PubMed ID: 32829134
[TBL] [Abstract][Full Text] [Related]
11. High specificity of spot urinary free metanephrines in diagnosis and prognosis of pheochromocytomas and paragangliomas by HPLC with electrochemical detection.
Zuo M; Zhen Q; Zhang X; Zou W; Yang X; Tian G; Shi Z; Li Q; Ding M
Clin Chim Acta; 2018 Mar; 478():82-89. PubMed ID: 29273559
[TBL] [Abstract][Full Text] [Related]
12. Levodopa therapy in Parkinson's disease: influence on liquid chromatographic tandem mass spectrometric-based measurements of plasma and urinary normetanephrine, metanephrine and methoxytyramine.
Eisenhofer G; Brown S; Peitzsch M; Pelzel D; Lattke P; Glöckner S; Stell A; Prejbisz A; Fassnacht M; Beuschlein F; Januszewicz A; Siegert G; Reichmann H
Ann Clin Biochem; 2014 Jan; 51(Pt 1):38-46. PubMed ID: 23873873
[TBL] [Abstract][Full Text] [Related]
13. [Metastatic risk factors in pheochromocytoma/paraganglioma].
Rebrova DV; Loginova OI; Vorobyev SL; Vorokhobina NV; Kozorezova ES; Indeykin FA; Savelyeva TV; Sleptsov IV; Chernikov RA; Fedorov EA; Semenov AA; Chinchuk IK; Shikhmagomedov SS; Alekseev MA; Krasnov LM; Rusakov VF
Probl Endokrinol (Mosk); 2023 Oct; 70(2):37-45. PubMed ID: 38796759
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service.
Kim JH; Moon H; Noh J; Lee J; Kim SG
Endocrinol Metab (Seoul); 2020 Mar; 35(1):157-164. PubMed ID: 32207276
[TBL] [Abstract][Full Text] [Related]
15. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
[TBL] [Abstract][Full Text] [Related]
16. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
[TBL] [Abstract][Full Text] [Related]
17. Overnight/first-morning urine free metanephrines and methoxytyramine for diagnosis of pheochromocytoma and paraganglioma: is this an option?
Peitzsch M; Kaden D; Pamporaki C; Langton K; Constantinescu G; Conrad C; Fliedner S; Sinnott RO; Prejbisz A; Därr R; Lenders JWM; Bursztyn M; Eisenhofer G
Eur J Endocrinol; 2020 May; 182(5):499-509. PubMed ID: 32187575
[TBL] [Abstract][Full Text] [Related]
18. False-positive results for pheochromocytoma associated with norepinephrine reuptake blockade.
Schürfeld R; Pamporaki C; Peitzsch M; Rayes N; Sabri O; Rohm S; Biemann R; Sandner B; Tönjes A; Eisenhofer G
Endocr Relat Cancer; 2024 Jan; 31(1):. PubMed ID: 37955319
[TBL] [Abstract][Full Text] [Related]
19. Predictors of recurrence of pheochromocytoma and paraganglioma: a multicenter study in Piedmont, Italy.
Parasiliti-Caprino M; Lucatello B; Lopez C; Burrello J; Maletta F; Mistrangelo M; Migliore E; Tassone F; La Grotta A; Pia A; Reimondo G; Giordano R; Giraudo G; Piovesan A; Ciccone G; Deandreis D; Limone P; Orlandi F; Borretta G; Volante M; Mulatero P; Papotti M; Aimaretti G; Terzolo M; Morino M; Pasini B; Veglio F; Ghigo E; Arvat E; Maccario M
Hypertens Res; 2020 Jun; 43(6):500-510. PubMed ID: 31586159
[TBL] [Abstract][Full Text] [Related]
20. Metastatic Pheochromocytomas and Abdominal Paragangliomas.
Granberg D; Juhlin CC; Falhammar H
J Clin Endocrinol Metab; 2021 Apr; 106(5):e1937-e1952. PubMed ID: 33462603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
